CTIS2023-507263-19-00进行中（未招募）1 期
A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation - 849-012
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 628
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Histologically or cytologically confirmed diagnosis of NSCLC with KRAS G12C mutation., Candidacy to receive treatment with docetaxel., Crossover Inclusion Criteria: Evidence of RECIST 1.1 defined disease progression on docetaxel per BICR, Crossover Inclusion Criteria: ECOG performance status 0 - 2.
排除标准
- •Prior treatment with an agent targeting KRAS G12C (e.g., AMG 510, sotorasib)., Active brain metastases, Crossover Exclusion Criteria: Receipt of any other systemic anti-cancer therapy after last administration of docetaxel on the study.
研究者
相似试验
招募中
3 期
A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C MutatioSCLC (Non-Small Cell Lung Cancer)Advanced Pulmonary Non-Small Cell CancerMetastatic Non- Small Cell Lung Cancer10027476NL-OMON56384Mirati Therapeutics, Inc.8
招募中
1 期
Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C MutatioAdvanced Non-Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-003645-11-NLMirati Therapeutics, Inc.450
招募中
3 期
Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C MutationAdvanced Non-Small Cell Lung Cancer2023-507263-19-00Mirati Therapeutics Inc.557
进行中（未招募）
1 期
Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C MutatioAdvanced Non-Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-003645-11-CZMirati Therapeutics, Inc.450
进行中（未招募）
1 期
Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C MutatioAdvanced Non-Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-003645-11-GRMirati Therapeutics, Inc.340